id stringlengths 9 11 | source stringclasses 1
value | title stringlengths 15 560 | text stringlengths 2k 153k |
|---|---|---|---|
PMC8520744 | core_pubmed_pmc | Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia | Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia Abstract Abstract Ulotaront (SEP‐363856) is a trace amine–associated receptor 1 agonist with 5‐HT 1A agonist activity in phase III development for the treatment of schizophrenia. The efficacy of ulotaront is not mediated by blockade of D 2 ... |
PMC6906394 | core_pubmed_pmc | Radiomodifying action, Pharmacokinetic and Biodistribution of Ethyl 3, 4, 5-trihydroxybenzoate-Implication in development of radiomitigator | Radiomodifying action, Pharmacokinetic and Biodistribution of Ethyl 3, 4, 5-trihydroxybenzoate-Implication in development of radiomitigator Abstract Abstract Ethyl 3, 4, 5-trihydroxybenzoate (GAE) is a major bioactive constituent of Hippophae Rhamnoides L . leaves and extract prepared from H. rhamnoides leaves exhibite... |
PMC9964656 | core_pubmed_pmc | Molecular and Biological Investigation of Isolated Marine Fungal Metabolites as Anticancer Agents: A Multi-Target Approach | Molecular and Biological Investigation of Isolated Marine Fungal Metabolites as Anticancer Agents: A Multi-Target Approach Abstract Cancer is the leading cause of death globally, with an increasing number of cases being annually reported. Nature-derived metabolites have been widely studied for their potential programme... |
PMC12746523 | core_pubmed_pmc | Drug Repositioning of Pegbing® for Essential Thrombocythemia: Insights from PK/PD Modeling and Extrapolation | Drug Repositioning of Pegbing® for Essential Thrombocythemia: Insights from PK/PD Modeling and Extrapolation Abstract Abstract Pegbing® (peginterferon alfa‐2b), a pegylated interferon‐alpha, is approved for the treatment of chronic hepatitis B (CHB) and C. One of its adverse effects is platelet (PLT) suppression. It is... |
PMC10704239 | core_pubmed_pmc | A pharmacokinetic study on red ginseng with furosemide in equine | A pharmacokinetic study on red ginseng with furosemide in equine Abstract Abstract Red ginseng (RG) is a popular ingredient in traditional Korean medicine that has various health benefits. It is commonly taken orally as a dietary supplement; however, its potential interactions with concomitantly administered drugs are ... |
PMC9420515 | core_pubmed_pmc | A Critical Review on the Pharmacodynamics and Pharmacokinetics of Non-steroidal Anti-inflammatory Drugs and Opioid Drugs Used in Reptiles | A Critical Review on the Pharmacodynamics and Pharmacokinetics of Non-steroidal Anti-inflammatory Drugs and Opioid Drugs Used in Reptiles Abstract Abstract Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are analgesics used for moderate to severe pain in many animals, including reptiles. However, reptilian d... |
PMC5237687 | core_pubmed_pmc | Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator | Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator Abstract Abstract Aim This open‐label study investigated the effect of belatacept on cytokine levels and on the pharmacokinetics of caffeine, losartan, omeprazole, dextr... |
PMC3044235 | core_pubmed_pmc | Analysis of isoflavones and flavonoids in human urine by UHPLC | Analysis of isoflavones and flavonoids in human urine by UHPLC Abstract Abstract A rapid, ultra high-performance liquid chromatographic (UHPLC) method has been developed and validated for simultaneous identification and analysis of the isoflavones genistein, daidzein, glycitin, puerarin, and biochanin A, and the flavon... |
PMC9464755 | core_pubmed_pmc | Effects of Acid-Reducing Agents on the Pharmacokinetics of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer | Effects of Acid-Reducing Agents on the Pharmacokinetics of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer Abstract Abstract Introduction Lazertinib is an irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Co-administration of T... |
PMC12109979 | core_pubmed_pmc | Targeting SHP2 with Natural Products: Exploring Saponin-Based Allosteric Inhibitors and Their Therapeutic Potential | Targeting SHP2 with Natural Products: Exploring Saponin-Based Allosteric Inhibitors and Their Therapeutic Potential Abstract Abstract SHP2, a non-receptor protein tyrosine phosphatase, plays a pivotal role in regulating intracellular signaling pathways, particularly the RAS/MAPK and PI3K/AKT cascades, which are critica... |
PMC11462627 | core_pubmed_pmc | SAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profile | SAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profile Abstract Abstract Background Esketamine, the first Food and Drug Administration-approved fast-acting antidepressant, has limited use because of its addictive properties. Although the combination o... |
PMC12816433 | core_pubmed_pmc | Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post‐Kala‐Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing | Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post‐Kala‐Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing Abstract Abstract Post‐kala‐azar dermal leishmaniasis (PKDL) involves a high macrophage burden in which the Leishmania parasit... |
PMC6126057 | core_pubmed_pmc | Evaluation of the Pharmacokinetics and Hepatoprotective Effects of Phillygenin in Mouse | Evaluation of the Pharmacokinetics and Hepatoprotective Effects of Phillygenin in Mouse Abstract Abstract Phillygenin is a bioactive intergradient in Osmanthus fragrans, a well-known food additive and Chinese traditional medicine. This study was to investigate the hepatoprotective effects and pharmacokinetics of philly... |
PMC5472428 | core_pubmed_pmc | Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins | Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins Abstract Abstract Finasteride (FIN) is a Class II candidate of the Biopharmaceutics Classification System (BCS). The lipophilic cavity of cyclodextrins (CyDs) enables it to construct a no... |
PMC5355565 | core_pubmed_pmc | An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice | An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice Abstract The study of the magnitude and variation of drug response is defined as pharmacodynamics (PDs). PD models examine plasma concentration and effect relationship. It can predict the archetypal effect ( E ) o... |
PMC4728832 | core_pubmed_pmc | The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients | The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients Abstract Background Artemether-lumefantrine is currently the most widely recommended treatment of uncomplicated malaria. Lopinavir–based antiretroviral therapy is the commonly recommended seco... |
PMC6273454 | core_pubmed_pmc | The Hedyotis diffusa Willd. (Rubiaceae): A Review on Phytochemistry, Pharmacology, Quality Control and Pharmacokinetics | The Hedyotis diffusa Willd. (Rubiaceae): A Review on Phytochemistry, Pharmacology, Quality Control and Pharmacokinetics Abstract Abstract Hedyotis diffusa Willd ( H. diffusa ) is a well-known Chinese medicine with a variety of activities, especially its anti-cancer effect in the clinic. Up to now, 171 compounds have be... |
PMC8237038 | core_pubmed_pmc | Inhibition of drug-metabolizing enzymes by Jingyin granules: implications of herb–drug interactions in antiviral therapy | Inhibition of drug-metabolizing enzymes by Jingyin granules: implications of herb–drug interactions in antiviral therapy Abstract Jingyin granules, a marketed antiviral herbal medicine, have been recommended for treating H1N1 influenza A virus infection and Coronavirus disease 2019 (COVID-19) in China. To fight viral d... |
PMC11429183 | core_pubmed_pmc | Concomitant Administration of Psychotropic and Prostate Cancer Drugs: A Pharmacoepidemiologic Study Using Drug–Drug Interaction Databases | Concomitant Administration of Psychotropic and Prostate Cancer Drugs: A Pharmacoepidemiologic Study Using Drug–Drug Interaction Databases Abstract Abstract Prostate cancer (PC) represents the second most common diagnosed cancer in men. The burden of diagnosis and long-term treatment may frequently cause psychiatric dis... |
PMC7584571 | core_pubmed_pmc | Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study | Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study Abstract DREAMM-2 ( NCT03525678 ) is an ongoing global, open-label, phase 2 study of single-agent belantamab mafodotin (belamaf; GSK2857916), a B-cell maturation an... |
PMC6764327 | core_pubmed_pmc | Using Pharmacogenomic Testing in Primary Care: Protocol for a Pilot Randomized Controlled Study | Using Pharmacogenomic Testing in Primary Care: Protocol for a Pilot Randomized Controlled Study Abstract Background Antidepressants are used by primary care providers to treat a variety of conditions, including (but not limited to) depression and anxiety. A trial-and-error approach is typically used to identify effecti... |
PMC6203364 | core_pubmed_pmc | Modeling three-dimensional invasive solid tumor growth in heterogeneous microenvironment under chemotherapy | Modeling three-dimensional invasive solid tumor growth in heterogeneous microenvironment under chemotherapy Abstract A systematic understanding of the evolution and growth dynamics of invasive solid tumors in response to different chemotherapy strategies is crucial for the development of individually optimized oncother... |
PMC12767029 | core_pubmed_pmc | Pharmacokinetics and Toxicity Overview of Active Compounds Berberine, Palmatine, and Jatrorrhizine From Fibraurea tinctoria Lour: Drug‐Likeness, ADMET Prediction, and In Vivo Extract Toxicity Assessment | Pharmacokinetics and Toxicity Overview of Active Compounds Berberine, Palmatine, and Jatrorrhizine From Fibraurea tinctoria Lour: Drug‐Likeness, ADMET Prediction, and In Vivo Extract Toxicity Assessment Abstract Abstract Fibraurea tinctoria Lour has long been used by the indigenous ethnic groups of Kalimantan in the tr... |
PMC11679493 | core_pubmed_pmc | The Application of the Design of Experiments and Artificial Neural Networks in the Development of a Fast and Straightforward HPLC-UV Method for Fluconazole Determination in Hemato-Oncologic Pediatric Patients and Its Adaptation to Therapeutic Drug Monitoring | The Application of the Design of Experiments and Artificial Neural Networks in the Development of a Fast and Straightforward HPLC-UV Method for Fluconazole Determination in Hemato-Oncologic Pediatric Patients and Its Adaptation to Therapeutic Drug Monitoring Abstract Objectives: This study aimed to develop an optimized... |
PMC3625411 | core_pubmed_pmc | A Comprehensive Review of Rapid-Onset Opioids for Breakthrough Pain | A Comprehensive Review of Rapid-Onset Opioids for Breakthrough Pain Abstract Abstract Breakthrough pain (BTP) is a transitory pain (reaching maximum severity in ∼15 minutes and lasting ∼60 minutes in patients with cancer) that occurs despite the management of chronic pain with long-term around-the-clock analgesia. BTP ... |
PMC7251226 | core_pubmed_pmc | Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes | Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes Abstract Highlights • Our study supports the feasibility of using rapid CYP2C19 genotyping among both patients with stable and acute coronary syndrome undergoing diagnostic coronary angiography, with intent to undergo ad hoc PCI, in real-wo... |
PMC9931433 | core_pubmed_pmc | Predicting changes in the pharmacokinetics of CYP3A‐metabolized drugs in hepatic impairment and insights into factors driving these changes | Predicting changes in the pharmacokinetics of CYP3A‐metabolized drugs in hepatic impairment and insights into factors driving these changes Abstract Abstract Physiologically based pharmacokinetic models, populated with drug‐metabolizing enzyme and transporter (DMET) abundance, can be used to predict the impact of hepat... |
PMC10957473 | core_pubmed_pmc | A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial | A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial Abstract Abstract New tuberculosis treatments are needed to address drug resistance, lengthy treatment duration and adverse reactions of available agents. GSK3036656 (ganfebor... |
PMC10372257 | core_pubmed_pmc | Oral pharmacokinetics of sulfadiazine and sulfamonomethoxine in female Holstein milking cows | Oral pharmacokinetics of sulfadiazine and sulfamonomethoxine in female Holstein milking cows Abstract The efficacy of orally administered drugs in cattle is thought to be slow because of the anatomical and physiological features of their forestomach. Thus, parenteral routes are mainly preferred to administer drugs. How... |
PMC12142690 | core_pubmed_pmc | No significant gender differences in driving-related skills following alcohol mixed with energy drinks during an experimental binge-drinking episode | No significant gender differences in driving-related skills following alcohol mixed with energy drinks during an experimental binge-drinking episode Abstract Introduction Consumption of alcohol mixed with energy drinks (AmEDs) is trendy among young people. It has been related to risk-taking behaviors like binge drinkin... |
PMC11064544 | core_pubmed_pmc | Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1 | Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1 Abstract ABSTRACT A fixed-dose combination (FDC) of 50 mg dolutegravir and 300 mg lamivudine is indicated for the treatment of HIV-1 infection. This ... |
PMC8135182 | core_pubmed_pmc | A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria | A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria Abstract Background For uncomplicated Plasmodium falciparum malaria, highly ef... |
PMC9505313 | core_pubmed_pmc | α-Tocopherol Pharmacokinetics in Adults with Cystic Fibrosis: Benefits of Supplemental Vitamin C Administration | α-Tocopherol Pharmacokinetics in Adults with Cystic Fibrosis: Benefits of Supplemental Vitamin C Administration Abstract Background: Numerous abnormalities in cystic fibrosis (CF) could influence tocopherol absorption, transportation, storage, metabolism and excretion. We hypothesized that the oxidative distress due to... |
PMC7359950 | core_pubmed_pmc | Rivaroxaban Precision Dosing Strategy for Real‐World Atrial Fibrillation Patients | Rivaroxaban Precision Dosing Strategy for Real‐World Atrial Fibrillation Patients Abstract Abstract Rivaroxaban is a direct‐acting oral anticoagulant approved to prevent strokes in patients with atrial fibrillation. Dosage recommendations are approved for all adult patients to receive either 15 mg or 20 mg once daily d... |
PMC8078274 | core_pubmed_pmc | NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas | NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas Abstract PURPOSE Patients with neurofibromatosis type 1 (NF1) frequently develop plexiform neurofibromas (PNs), which can cause significa... |
PMC10507354 | core_pubmed_pmc | Retrospective quantification of clinical abdominal DCE-MRI using pharmacokinetics-informed deep learning: a proof-of-concept study | Retrospective quantification of clinical abdominal DCE-MRI using pharmacokinetics-informed deep learning: a proof-of-concept study Abstract Introduction Dynamic contrast-enhanced (DCE) MRI has important clinical value for early detection, accurate staging, and therapeutic monitoring of cancers. However, conventional mu... |
PMC6259028 | core_pubmed_pmc | Incidence and risk factors for potentially suboptimal serum concentrations of vancomycin during cardiac surgery | Incidence and risk factors for potentially suboptimal serum concentrations of vancomycin during cardiac surgery Abstract Abstract AIM To investigate the incidence and risk factors for vancomycin concentrations less than 10 mg/L during cardiac surgery. METHODS In this prospective study, patients undergoing cardiac surge... |
PMC10725260 | core_pubmed_pmc | Apixaban and rivaroxaban's physiologically‐based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side | Apixaban and rivaroxaban's physiologically‐based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side Abstract Abstract When used in real‐world conditions, substantial interindividual variations in direct oral anticoagulant (DOAC) plasma concen... |
PMC3824374 | core_pubmed_pmc | Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus | Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus Abstract Abstract Background and Objectives Sifalimumab is a fully human immunoglobulin G1κ monoclonal antibody that binds to and neutralizes a majority of the subtypes of human interfer... |
PMC9292347 | core_pubmed_pmc | Randomized, Double‐Blind, Controlled Study to Evaluate Safety and Pharmacokinetics of Single Ascending Doses of ASP5354, an Investigational Imaging Product, in Healthy Adult Volunteers | Randomized, Double‐Blind, Controlled Study to Evaluate Safety and Pharmacokinetics of Single Ascending Doses of ASP5354, an Investigational Imaging Product, in Healthy Adult Volunteers Abstract Abstract Intraoperative ureter identification helps reduce the risk of ureteral injury. Currently, no suitable agents for real... |
PMC4441949 | core_pubmed_pmc | Fundament and Prerequisites for the Application of an Antifungal TDM Service | Fundament and Prerequisites for the Application of an Antifungal TDM Service Abstract Abstract Therapeutic drug monitoring (TDM) involves the measurement of plasma or serum drug concentration to adapt dosages to achieve predefined target concentrations that are associated with optimal clinical response while minimizing... |
PMC6061399 | core_pubmed_pmc | Pharmacokinetics of a Novel Sildenafil Orodispersible Film Administered by the Supralingual and the Sublingual Route to Healthy Men | Pharmacokinetics of a Novel Sildenafil Orodispersible Film Administered by the Supralingual and the Sublingual Route to Healthy Men Abstract Background Sildenafil was the first selective drug available on the market as oral therapy for erectile dysfunction (ED). A novel sildenafil orodispersible film (ODF) for ED treat... |
PMC3731828 | core_pubmed_pmc | Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-Patient Study Designs in Psoriasis | Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-Patient Study Designs in Psoriasis Abstract Clinical trial simulation (CTS) and model-based meta-analysis (MBMA) can increase our understanding of small, first-in-patient (FIP) trial design performance to inform Phase 2 dec... |
PMC9006454 | core_pubmed_pmc | The effect of a loading dose of meropenem on outcomes of patients with sepsis treated by continuous renal replacement: study protocol for a randomized controlled trial | The effect of a loading dose of meropenem on outcomes of patients with sepsis treated by continuous renal replacement: study protocol for a randomized controlled trial Abstract Abstract Background Sepsis and continuous renal replacement therapy (CRRT) are both responsible for the alterations of the pharmacokinetics of ... |
PMC8361687 | core_pubmed_pmc | A narrative review of the importance of pharmacokinetics and drug–drug interactions of preventive therapies in migraine management | A narrative review of the importance of pharmacokinetics and drug–drug interactions of preventive therapies in migraine management Abstract Abstract Objective To review the pharmacokinetics of major classes of migraine preventives and the clinical implications of drug–drug interactions (DDIs) with the use of these ther... |
PMC4335612 | core_pubmed_pmc | In vivo determination of the diclofenac skin reservoir: comparison between passive, occlusive, and iontophoretic application | In vivo determination of the diclofenac skin reservoir: comparison between passive, occlusive, and iontophoretic application Abstract Abstract Aim There is scarce information concerning the pharmacodynamic behavior of topical substances used in the physiotherapy setting. The aim of the present study was to estimate the... |
PMC9917293 | core_pubmed_pmc | The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of Tyrosine Kinase Inhibitors | The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of Tyrosine Kinase Inhibitors Abstract Tyrosine kinase inhibitors (TKIs) decisively contributed in revolutionizing the therapeutic approach to cancer, offering non-invasive, tolerable therapies for a better qual... |
PMC9246813 | core_pubmed_pmc | The Extension of the LeiCNS-PK3.0 Model in Combination with the “Handshake” Approach to Understand Brain Tumor Pathophysiology | The Extension of the LeiCNS-PK3.0 Model in Combination with the “Handshake” Approach to Understand Brain Tumor Pathophysiology Abstract Abstract Micrometastatic brain tumor cells, which cause recurrence of malignant brain tumors, are often protected by the intact blood–brain barrier (BBB). Therefore, it is essential to... |
PMC6896740 | core_pubmed_pmc | Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects | Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects Abstract Background PF-06650833 is a potent, selective inhibitor of interleukin-1 re... |
PMC6586986 | core_pubmed_pmc | Orodispersible minitablets of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study | Orodispersible minitablets of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study Abstract Introduction Treatment of paediatric heart failure is based on paradigms extensively tested in the adult population assuming ... |
PMC11521888 | core_pubmed_pmc | Family Malvaceae: a potential source of secondary metabolites with chemopreventive and anticancer activities supported with in silico pharmacokinetic and pharmacodynamic profiles | Family Malvaceae: a potential source of secondary metabolites with chemopreventive and anticancer activities supported with in silico pharmacokinetic and pharmacodynamic profiles Abstract Introduction Cancer is the second most widespread cause of mortality following cardiovascular disorders, and it imposes a heavy glob... |
PMC9298821 | core_pubmed_pmc | Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone | Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone Abstract Aims Addition of isatuximab (Isa) to pomalidomide/dexamethasone (Pd) significantly improved progression‐free survival (PFS) in patients with relapsed/refractory m... |
PMC5583966 | core_pubmed_pmc | Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation | Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation Abstract Abstract Background Exenatide (EXT), the first glucagon-like peptide-1 receptor agonist, has been approved as an adjunctive therapy for patients with type 2 diabetes. Due to EXT’s ... |
PMC3257304 | core_pubmed_pmc | Two-Drug Antimicrobial Chemotherapy: A Mathematical Model and Experiments with Mycobacterium marinum | Two-Drug Antimicrobial Chemotherapy: A Mathematical Model and Experiments with Mycobacterium marinum Abstract Abstract Multi-drug therapy is the standard-of-care treatment for tuberculosis. Despite this, virtually all studies of the pharmacodynamics (PD) of mycobacterial drugs employed for the design of treatment proto... |
PMC12588662 | core_pubmed_pmc | Exploring Health Care Professionals' Engagement With a Precision Dosing Calculator and Supporting Clinical Information: Insights From an Eye-Tracking and Usability Study | Exploring Health Care Professionals' Engagement With a Precision Dosing Calculator and Supporting Clinical Information: Insights From an Eye-Tracking and Usability Study Abstract Supplemental Digital Content is Available in the Text. Background: Pharmacokinetic-based dosing calculators for individualized drug dosing re... |
PMC11895769 | core_pubmed_pmc | A Tutorial and Use Case Example of the eXtreme Gradient Boosting (XGBoost) Artificial Intelligence Algorithm for Drug Development Applications | A Tutorial and Use Case Example of the eXtreme Gradient Boosting (XGBoost) Artificial Intelligence Algorithm for Drug Development Applications Abstract ABSTRACT Approaches to artificial intelligence and machine learning (AI/ML) continue to advance in the field of drug development. A sound understanding of the underlyin... |
PMC9056705 | core_pubmed_pmc | Sophora interrupta Bedd. root-derived flavonoids as prominent antiviral agents against Newcastle disease virus † | Sophora interrupta Bedd. root-derived flavonoids as prominent antiviral agents against Newcastle disease virus † Abstract Abstract The discovery and development of novel antiviral drugs from natural sources is continuously increasing due to limitations of currently available drugs such as toxic side effects, drug resid... |
PMC12313516 | core_pubmed_pmc | Fluorinated small molecule derivatives in cancer immunotherapy: emerging frontiers and therapeutic potential | Fluorinated small molecule derivatives in cancer immunotherapy: emerging frontiers and therapeutic potential Abstract Immunotherapy has revolutionized cancer treatment by leveraging the body’s immune system to recognize and eliminate tumor cells. While monoclonal antibodies and checkpoint inhibitors have shown dramatic... |
PMC8032617 | core_pubmed_pmc | Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies | Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies Abstract Abstract Purpose An influential covariate for pharmacokinetics is (body) size. Recently, the method of estimation of normal fat mass (NFM) has been advocated. Here, the relative contribution of fat mass, estimated as a fraction fat... |
PMC10974317 | core_pubmed_pmc | Anti-COVID Drugs (MMV COVID Box) as Leishmanicidal Agents: Unveiling New Therapeutic Horizons | Anti-COVID Drugs (MMV COVID Box) as Leishmanicidal Agents: Unveiling New Therapeutic Horizons Abstract Abstract Leishmaniasis, a neglected tropical disease, poses a significant global health challenge, necessitating the urgent development of innovative therapies. In this study, we aimed to identify compounds from the C... |
PMC5995788 | core_pubmed_pmc | Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers | Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers Abstract Objective The aim of this study was to summarise the pharmacokinetic findings from eight phase I studies in healthy volunteers given oral AZD5069, a selective small-molecule CXCR2 antagonis... |
PMC7192969 | core_pubmed_pmc | Potential synergic mechanism of Wutou-Gancao herb-pair by inhibiting efflux transporter P-glycoprotein | Potential synergic mechanism of Wutou-Gancao herb-pair by inhibiting efflux transporter P-glycoprotein Abstract Wutou-Gancao herb-pair is extensively used to attenuate the toxicity and enhance the efficacy of aconite. In this study, potential synergic mechanism of the herb pair was investigated by utilizing multiple ap... |
PMC6342900 | core_pubmed_pmc | Propofol-sparing effect of different concentrations of dexmedetomidine | Propofol-sparing effect of different concentrations of dexmedetomidine Abstract Abstract Background The pharmacodynamics of propofol are closely linked to gender. Dexmedetomidine can decrease propofol needs during propofol anesthesia. The aim of this study was to compare the gender differences on the calculated effect ... |
PMC8592519 | core_pubmed_pmc | Metaheuristics for pharmacometrics | Metaheuristics for pharmacometrics Abstract Abstract Metaheuristics is a powerful optimization tool that is increasingly used across disciplines to tackle general purpose optimization problems. Nature‐inspired metaheuristic algorithms is a subclass of metaheuristic algorithms and have been shown to be particularly flex... |
PMC8225540 | core_pubmed_pmc | Fast screening of covariates in population models empowered by machine learning | Fast screening of covariates in population models empowered by machine learning Abstract Abstract One of the objectives of Pharmacometry (PMX) population modeling is the identification of significant and clinically relevant relationships between parameters and covariates. Here, we demonstrate how this complex selection... |
PMC12906696 | core_pubmed_pmc | Optimal Dosage Justification for Datopotamab Deruxtecan in HR ‐Positive/ HER2 ‐Negative Breast Cancer Through Model‐Informed Drug Development Approaches | Optimal Dosage Justification for Datopotamab Deruxtecan in HR ‐Positive/ HER2 ‐Negative Breast Cancer Through Model‐Informed Drug Development Approaches Abstract ABSTRACT Project Optimus has been reforming the dose selection and optimization paradigm in oncology. In this context, model‐informed drug development (MIDD) ... |
PMC8760805 | core_pubmed_pmc | Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? | Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? Abstract Anti-CTLA-4 and anti-PD-1/PD-L1 immune checkpoint inhibitors are therapeutic monoclonal antibodies that do not target cancer cells but are designed to reactivate or promote antitumor immunity. Dosing and scheduling of these biolo... |
PMC8921207 | core_pubmed_pmc | Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings | Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings Abstract Abstract Patients with breast cancer frequently experience financial hardship, often due to the high costs of anti-cancer drugs. We sought to develop alternative trastuzumab dosing s... |
PMC7012273 | core_pubmed_pmc | Pharmacokinetic Interactions between Cardiovascular Medicines and Plant Products | Pharmacokinetic Interactions between Cardiovascular Medicines and Plant Products Abstract The growing use of plant products among patients with cardiovascular pharmacotherapy raises the concerns about their potential interactions with conventional cardiovascular medicines. Plant products can influence pharmacokinetics ... |
PMC9487539 | core_pubmed_pmc | Quantitative Pharmacodynamic Characterization of Resistance versus Heteroresistance of Colistin in E. coli Using a Semimechanistic Modeling of Killing Curves | Quantitative Pharmacodynamic Characterization of Resistance versus Heteroresistance of Colistin in E. coli Using a Semimechanistic Modeling of Killing Curves Abstract ABSTRACT Heteroresistance corresponds to the presence, in a bacterial isolate, of an initial small subpopulation of bacteria characterized by a significa... |
PMC9875126 | core_pubmed_pmc | Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non–small cell lung cancer after a single 200 mg administration | Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non–small cell lung cancer after a single 200 mg administration Abstract Abstract Background Pembrolizumab is a well-tolerated biologic agent with a potentially stable and durable anti-tumor response. Unfortunately, discontinuation of therapy can... |
PMC11693508 | core_pubmed_pmc | Pharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS/MS | Pharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS/MS Abstract Introduction MRTX1133 is a selective and reversible small molecule inhibitor of KRAS (G12D), which significantly delays the progression of solid tumors. However, no study on the absorption, distribution, and excret... |
PMC12167915 | core_pubmed_pmc | Middle‐Out Physiologically Based Pharmacokinetic Modeling to Support Pediatric Dosing Recommendation for Alectinib | Middle‐Out Physiologically Based Pharmacokinetic Modeling to Support Pediatric Dosing Recommendation for Alectinib Abstract ABSTRACT Adult patients with anaplastic lymphoma kinase positive (ALK+) advanced non–small‐cell lung cancer (NSCLC) are treated with 600 mg alectinib twice daily (BID) as first‐line treatment. ALK... |
PMC3460787 | core_pubmed_pmc | Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review | Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review Abstract Abstract The pharmacokinetics of beta-lactam antibiotics in intensive care patients may be profoundly altered due to the dynamic, unpredictable pathophysiological changes that occur ... |
PMC11401219 | core_pubmed_pmc | In vivo SPECT imaging of Tc-99m radiolabeled exosomes from human umbilical-cord derived mesenchymal stem cells in small animals | In vivo SPECT imaging of Tc-99m radiolabeled exosomes from human umbilical-cord derived mesenchymal stem cells in small animals Abstract Abstract Extracellular vesicles derived from human umbilical cord-derived mesenchymal stem cells (UCMSC-EVs) have been postulated to have therapeutic potential for various diseases. H... |
PMC9284023 | core_pubmed_pmc | The Surface Area to Volume Ratio Changes the Pharmacokinetic and Pharmacodynamic Parameters in the Subcutaneous Tissue Cage Model: As Illustrated by Carprofen in Sheep | The Surface Area to Volume Ratio Changes the Pharmacokinetic and Pharmacodynamic Parameters in the Subcutaneous Tissue Cage Model: As Illustrated by Carprofen in Sheep Abstract Abstract Introduction Pharmacokinetic and pharmacodynamic models can be powerful tools for predicting outcomes. Many models are based on repeti... |
PMC7848311 | core_pubmed_pmc | Evaluation of urine concentrations of amoxicillin and clavulanate in cats | Evaluation of urine concentrations of amoxicillin and clavulanate in cats Abstract Abstract Background To characterize urinary isolates, the Clinical and Laboratory Standards Institute (CLSI) uses an amoxicillin breakpoint for cats based on plasma (not urine) drug concentrations (≤0.25 μg/mL), but a urine‐specific brea... |
PMC8177775 | core_pubmed_pmc | Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study | Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study Abstract Abstract Milademetan (DS‐3032, RAIN‐32) is an orally available mouse double minute 2 (MDM2) antagonist with potential antineoplastic activity owing to increase in p53 activity through interrupt... |
PMC6274100 | core_pubmed_pmc | Relevance of the Pharmacokinetic and Pharmacodynamic Profiles of Puerariae lobatae Radix to Aggregation of Multi-Component Molecules in Aqueous Decoctions | Relevance of the Pharmacokinetic and Pharmacodynamic Profiles of Puerariae lobatae Radix to Aggregation of Multi-Component Molecules in Aqueous Decoctions Abstract The complexity of traditional Chinese medicines (TCMs) is related to their multi-component system. TCM aqueous decoction is a common clinical oral formulati... |
PMC12036344 | core_pubmed_pmc | EDP‐323, a First‐In‐Class, Once‐Daily, Oral L‐Protein Inhibitor for the Treatment of RSV: Results From a Phase 1 Study in Healthy Adults | EDP‐323, a First‐In‐Class, Once‐Daily, Oral L‐Protein Inhibitor for the Treatment of RSV: Results From a Phase 1 Study in Healthy Adults Abstract ABSTRACT Respiratory syncytial virus (RSV) remains a significant health concern, particularly for vulnerable populations. Despite preventive strategies, there remains a need ... |
PMC10088884 | core_pubmed_pmc | Nanoformulation of Paclitaxel: Exploring the Cyclodextrin / PLGA Nano Delivery Carrier to Slow Down Paclitaxel Release, Enhance Accumulation in Vivo | Nanoformulation of Paclitaxel: Exploring the Cyclodextrin / PLGA Nano Delivery Carrier to Slow Down Paclitaxel Release, Enhance Accumulation in Vivo Abstract Abstract Background: Improving the aggregation and penetration in tumor sites increases the anti-tumor efficacy of nanomedicine. In the current study, we designed... |
PMC12771191 | core_pubmed_pmc | Repurposed Arylidene-hydrazinyl-1,3-thiazoles as Multitarget Anti-Alzheimer’s Agents via Combined Computational and Experimental Studies | Repurposed Arylidene-hydrazinyl-1,3-thiazoles as Multitarget Anti-Alzheimer’s Agents via Combined Computational and Experimental Studies Abstract Abstract In quest of new and potent multitarget therapeutics for Alzheimer’s disease (AD), a series of recently synthesized arylidene-hydrazinyl-thiazoles were repurposed as ... |
PMC6152078 | core_pubmed_pmc | Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy | Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy Abstract Abstract Antibody-drug conjugates (ADCs) are a class of highly potent biopharmaceutical drugs generated by conjugating cytotoxic drugs with specific monoclonal antibodies through appropriate linkers. Specific antibodies used to guide potent wa... |
PMC7564657 | core_pubmed_pmc | A Web-Based Pharmacogenomics Search Tool for Precision Medicine in Perioperative Care | A Web-Based Pharmacogenomics Search Tool for Precision Medicine in Perioperative Care Abstract Abstract Background: Precision medicine represents an evolving approach to improve treatment efficacy by modifying it to individual patient’s gene variation. Pharmacogenetics, an applicable branch of precision medicine, ident... |
PMC7847018 | core_pubmed_pmc | Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy | Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy Abstract Abstract Background To evaluate the transmembrane clearance (CL TM ) of apixaban during modeled in vitro continuous renal replacement therapy (CRRT), assess protein binding and circuit adsorption, and provi... |
PMC8912535 | core_pubmed_pmc | Polymeric Nanoparticles-Loaded Hydrogels for Biomedical Applications: A Systematic Review on In Vivo Findings | Polymeric Nanoparticles-Loaded Hydrogels for Biomedical Applications: A Systematic Review on In Vivo Findings Abstract Abstract Clinically available medications face several hurdles that limit their therapeutic activity, including restricted access to the target tissues due to biological barriers, low bioavailability, ... |
PMC8020375 | core_pubmed_pmc | In silico approach to understand the epigenetic mechanism of SARS-CoV-2 and its impact on the environment | In silico approach to understand the epigenetic mechanism of SARS-CoV-2 and its impact on the environment Abstract The novel coronavirus (2019-nCoV) has led to the apex pandemic in 2020, responsible for the recent sequential spread. The 2019-nCoV has been discerned to be a Beta-BAT-SARS-CoV-2 lineage. The gene ontology... |
PMC4639630 | core_pubmed_pmc | Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics | Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics Abstract Preclinical studies show that GABA exerts anti-diabetic effects in rodent models of type 1 diabetes. Because little is known about its absorption and effects in humans, we investigated the pharmacokinetics and pharmacodynamics of GABA i... |
PMC2998804 | core_pubmed_pmc | A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients | A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients Abstract Abstract Purpose A Phase I dose-escalation study was performed to determine the maximum tolerated dose (MTD) of the immunotoxin VB4-8... |
PMC6193352 | core_pubmed_pmc | Clinical Pharmacology of Hormonal Emergency Contraceptive Pills | Clinical Pharmacology of Hormonal Emergency Contraceptive Pills Abstract Abstract Emergency contraceptives play a major role in preventing unwanted pregnancy. The use of emergency contraceptives is characterized by myths and lack of knowledge by both health professionals and users. The main objective of this paper is t... |
PMC4137827 | core_pubmed_pmc | Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects | Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects Abstract Abstract Aims This study investigated relevant pharmacodynamic and pharmacokinetic parameters during the transition from warfarin to rivaroxaban in healthy male subjects. Methods Nin... |
PMC8359294 | core_pubmed_pmc | Physiological parameter values for physiologically based pharmacokinetic models in food‐producing animals. Part III: Sheep and goat | Physiological parameter values for physiologically based pharmacokinetic models in food‐producing animals. Part III: Sheep and goat Abstract Abstract This report is the third in a series of studies that aimed to compile physiological parameters related to develop physiologically based pharmacokinetic (PBPK) models for ... |
PMC8388958 | core_pubmed_pmc | Recent Advances and Challenges in Nanodelivery Systems for Antimicrobial Peptides (AMPs) | Recent Advances and Challenges in Nanodelivery Systems for Antimicrobial Peptides (AMPs) Abstract Antimicrobial peptides (AMPs) can be used as alternative therapeutic agents to traditional antibiotics. These peptides have abundant natural template sources and can be isolated from animals, plants, and microorganisms. Th... |
PMC9202903 | core_pubmed_pmc | Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates | Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates Abstract Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease caused by uncontrolled complement activation; effective and approved treatments include terminal complement inhibition. This stud... |
PMC5421598 | core_pubmed_pmc | Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor | Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor Abstract Despite decades of research in the epidermal growth factor receptor (EGFR) signalling field, and many targeted anti-cancer drugs that have been tested clinically, the success rate for these a... |
PMC5286489 | core_pubmed_pmc | Pharmacokinetic Properties of Adenosine Amine Congener in Cochlear Perilymph after Systemic Administration | Pharmacokinetic Properties of Adenosine Amine Congener in Cochlear Perilymph after Systemic Administration Abstract Noise-induced hearing loss (NIHL) is a global health problem affecting over 5% of the population worldwide. We have shown previously that acute noise-induced cochlear injury can be ameliorated by administ... |
PMC8082819 | core_pubmed_pmc | Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA) | Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA) Abstract Abstract Background Anti-tumor necrosis factor (TNF) drugs have improved the prognosis for juvenile idiopathic arthritis (JIA) sig... |
PMC6435784 | core_pubmed_pmc | Gut Microbiota-Based Pharmacokinetics and the Antidepressant Mechanism of Paeoniflorin | Gut Microbiota-Based Pharmacokinetics and the Antidepressant Mechanism of Paeoniflorin Abstract Abstract Paeoniflorin, the main component of Xiaoyao Wan, presents low oral bioavailability and unclear antidepressant mechanism. To elucidate the potential reasons for the low bioavailability of paeoniflorin and explore its... |
PMC6843799 | core_pubmed_pmc | Pharmacokinetics and Metabolite Profiling of Trepibutone in Rats Using Ultra-High Performance Liquid Chromatography Combined With Hybrid Quadrupole-Orbitrap and Triple Quadrupole Mass Spectrometers | Pharmacokinetics and Metabolite Profiling of Trepibutone in Rats Using Ultra-High Performance Liquid Chromatography Combined With Hybrid Quadrupole-Orbitrap and Triple Quadrupole Mass Spectrometers Abstract Abstract Trepibutone was widely used for cholelithiasis, cholecystitis, biliary tract dyskinesia, cholecystectomy... |
PMC11427509 | core_pubmed_pmc | Relationship between preinduction electroencephalogram patterns and propofol sensitivity in adult patients | Relationship between preinduction electroencephalogram patterns and propofol sensitivity in adult patients Abstract Abstract Purpose To determine the precise induction dose, an objective assessment of individual propofol sensitivity is necessary. This study aimed to investigate whether preinduction electroencephalogram... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.